공시 • Jun 15
Conexeu Sciences Inc. Announces Management and Committee Changes, Effective June 15, 2026
Conexeu Sciences Inc. announced additions to its leadership team, effective June 15, 2026. Conexeu has appointed Ana Bastiani-Posner, April Burke, and Andrew Costa to its Board of Directors. The appointments add significant experience across healthcare, finance, capital markets, operations, and strategic growth initiatives as Conexeu continues advancing its proprietary CXU™ platform, and long-term commercialization strategy. The Company also announced the appointment of Co-Founder and Director David Bogart as Chief Commercial Officer. Bogart will lead commercialization efforts and strategic operational initiatives, having helped shape Conexeu's platform and regulatory strategy from inception. He has foundational knowledge of the intellectual property and multi-indication pathway to expand Conexeu’s presence within the regenerative medicine sector. Additionally, Melinda Farina, the founder of Integrated Aesthetics Consulting Inc. and Beauty Brokers Inc. joins Conexeu’s advisory board. Farina is a trusted leader and patient advocate in the aesthetics space. The Company also announced updated board committee assignments across its Audit, Compensation, and Nominating and Corporate Governance Committees. Board and Officer Appointments, Ana Bastiani-Posner, MBA– Compensation Committee (Chair), Audit Committee. Bastiani-Posner is a seasoned financial expert and C-suite executive with more than 20 years of leadership experience across Fortune 500 companies and research organizations. She currently serves as Executive Vice President and Chief Financial Officer of Kyowa Kirin North America, where she helps oversee approximately $1.2 billion in annual revenue. Ana brings extensive experience in healthcare operations, financial strategy, mergers and acquisitions, and corporate governance, with previous senior leadership roles at Allergan, New York Genome Center, Schering-Plough, and Novartis. April Burke– Audit Committee, Compensation Committee, Burke is a finance executive with experience spanning public companies, private equity-backed organizations, and privately held businesses. April currently serves as Executive Vice President and Chief Financial Officer of Lucid Hearing, where she brings expertise in capital allocation, financial operations, mergers and acquisitions, IPO readiness and organizational growth initiatives. Andrew Costa, MBA – Audit Committee (Chair), Nominating and Corporate Governance Committee, Costa is an investor, operator, and growth equity executive with fifteen years of experience across private equity, investment banking, and military leadership. He is the Co-Managing Partner of RX3 Growth Partners, a consumer-focused growth equity firm investing in health, wellness, and active-lifestyle brands, where he leads investments and serves on the boards of multiple portfolio companies, including Therabody. He previously held investment banking roles at Morgan Stanley and J.P. Morgan, advising companies on capital formation, public offerings, and M&A. Earlier in his career, Costa served as a Captain in the United States Air Force. He brings to the Board extensive capital markets expertise, financial oversight experience, and the operational discipline of his military service. David Bogart – Chief Commercial Officer, Director, Bogart is a capital markets advisor, investor relations strategist, and business executive with experience supporting emerging growth and publicly traded companies across North America. He has advised companies on more than $75 million in capital formation and brings extensive expertise in public market strategy, investor communications, financing, mergers and acquisitions, and go-public transactions. Melinda Farina – Advisor, Farina, known as “The Beauty Broker,” is an entrepreneur, consultant, and recognized leader in the medical aesthetics and beauty industry with nearly three decades of experience spanning aesthetics, dentistry, practice management, and business development. As founder of Integrated Aesthetics Consulting Inc. and Beauty Brokers Inc., she has advised leading physicians, practices, and aesthetic brands across the industry, bringing extensive expertise in consumer health, brand development, market positioning, and growth strategy. These appointments come during a period of significant momentum for Conexeu, following its recent Nasdaq listing, bell-ringing ceremony, and the continued advancement of its proprietary regenerative tissue technologies, including the preclinical development of B.R.E.A.S.T.™, a novel 3D-bioprinted breast matrix designed to advance reconstruction beyond implant-based replacement and toward tissue regeneration. The Company is focused on developing regenerative solutions designed to support the body's natural healing and tissue restoration processes across a range of potential applications, including wound care, soft tissue restoration, and breast reconstruction.